Per Bo Pedersen Fischer
Director Ejecutivo en Helion Biotech ApS .
Perfil
Per Bo Pedersen Fischer is the founder and the Chief Executive Officer of Helion Biotech ApS, which was founded in 2008.
He is also currently the Chief Executive Officer of Minervax ApS.
Dr. Fischer previously held the position of President & Chief Executive Officer at Azanta Danmark A from 2000 to 2003.
He also worked as a Principal at Novo Nordisk A and Bavarian Nordic A.
Dr. Fischer obtained a doctorate degree from the University of Oxford in 1996 and a graduate degree from the University of Southern Denmark in 1992.
Cargos activos de Per Bo Pedersen Fischer
| Empresas | Cargo | Inicio |
|---|---|---|
Helion Biotech ApS
 Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark. | Director Ejecutivo | 01/01/2008 |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Director Ejecutivo | 05/04/2011 |
Antiguos cargos conocidos de Per Bo Pedersen Fischer.
| Empresas | Cargo | Fin |
|---|---|---|
Azanta Danmark A/S
 Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Presidente | 01/01/2003 |
| BAVARIAN NORDIC A/S | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Formación de Per Bo Pedersen Fischer.
| University of Southern Denmark | Graduate Degree |
| University of Oxford | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| BAVARIAN NORDIC A/S | Health Technology |
| Empresas privadas | 3 |
|---|---|
Azanta Danmark A/S
Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Health Technology |
Helion Biotech ApS
Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark. | Health Technology |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Bolsa de valores
- Insiders
- Per Bo Pedersen Fischer
